Linagliptin-metformin combo boosts glucose control in type 2 diabetes

05/31/2012 | Endocrine Today

A higher-dose combination of linagliptin and metformin fared better than a high-dose metformin-only treatment in lowering blood glucose levels in patients with type 2 diabetes, a study presented at the American Association of Clinical Endocrinologists meeting showed. The combination treatment was also very well-tolerated in patients over 18 months, a researcher said.

View Full Article in:

Endocrine Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD